Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2768)	2/1/2001 9:08:53 PM
From: Miljenko Zuanic	Read Replies (2) of 52153

<<Indeed, leading genomics outfits saw their shares slide Wednesday: Millennium (MLNM:Nasdaq - news) dropped $2.75, or 5.2%, to $50.12, Incyte (INCY:Nasdaq - news) slipped 44 cents to $27.88 and Celera (CRA:NYSE - news) dropped $2.75, or 5.3%, to $49.01.>> What MLNM have to do with INCY and CLRA? Why they are constantly putting this bios together and comparing perfect bio-model with service-bios? Where are underwriters and analysts from last year? When they were selling ANYTHING to ANYONE at huge PREMIUM? Where is their voice now? Isn’t Lehman who have note in Dec. that excessive supply from the luck-up expiration (from IPO and SPO) will bring sector down in 1Q, and that they ARE consider THIS as BUYING OPORTUNITY? I guess, they need to be sure about BRING DOWN. <g> I am pissed off. Pissed off big time! When will HONEST and TRUTFUL analyst emerge from this Universe and put facts together, forever??? Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next